METROSIL
2.3.2016 04:01:55 CET | Business Wire | Press release
Metrosil , the world leader in silicon carbide non-linear resistors (called varistors) today announced the launch of its new range of De-Excitation Units - the “Metrosil 8000 Series”, designed to protect large electrical generators. The all-new 8000 Series (protected by Registered Design) has been developed around an improved ergonomic structure, an industry first, providing not only protection for the varistor discs, but also simplifying the installation of the units. Another unique feature is the inclusion of a high energy test certificate with every 8000 Series unit, providing proof that the varistors perform as required. De-Excitation varistors protect electricity generating equipment (for example in hydropower and nuclear installations) from the damaging effects of powerful high energy surges.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160301006459/en/
8000 Series features include:
- Protective bar to prevent accidental disc damage
- Anti-tamper device to ensure unit integrity
- Ergonomic handles for easy carrying and installation
- Robust, easy-access connection points
- Range of standard footprints enables consistent installation
- Nameplate –permanently displays the unit’s specification details
- Each unit shipped with certification of high energy testing
- Clearly labelled with High Energy Test “Pass” badge
James O’Brien, Metrosil’s Product Group Director, commented “Metrosil constantly innovates and responds to customer feedback. With its new design, anti-tamper and ergonomic features, the 8000 Series is a more robust, long-lasting product. All Metrosil excitation products are tested to 100% of its specification – it’s part of what makes us unique in the industry, and we’re thrilled to launch another Metrosil first for the power generation industry.”
The Metrosil commercial team will be showing the 8000 Series at industry trade shows and also to individual utilities and power generation companies. To arrange a Metrosil 8000 Series visit, email requests should be sent to Ian Rowley, Metrosil’s Business Development Manager: ianrowley@mimaterials.com .
Ends
About Metrosil
Metrosil is the leading brand of high performance over-voltage protection devices for a wide range of power generation and transmission applications around the globe. It is a product of M&I Materials Limited in Manchester, UK. Since 1936, millions of Metrosil varistors have been sold throughout the world, used in flagship power projects including:
- Three Gorges Hydroelectric Dam, China
- La Grande, Canada
- Grand Coulee Dam, USA
- Itaipu, Brazil/Paraguay
About M&I Materials Limited
M&I Materials Limited is an international manufacturing company producing Specialist Materials for Industry and Science to customers located in more than sixty countries worldwide. www.mimaterials.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301006459/en/
Contact:
M&I Materials Ltd
Ian Rowley, Metrosil Business Development
Manager
Tel: +44 (0) 161 864 5490
E-mail: ianrowley@mimaterials.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom